A patient diagnosed with the aggressive brain tumor glioblastoma typically has only 15 months to live. The grim prognosis can lead to multiple surgeries to remove and then test suspected tumors. But what if clinicians could determine whether a suspicious tumor is benign or malignant without putting patients under the knife?